Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Biosimilars Sector?

The dimension of the biosimilars market has expanded swiftly over the recent years. The market is projected to catapult from $18.65 billion in 2024 to $21.85 billion in 2025, with a compound annual growth rate (CAGR) of 17.2%. Factors contributing to the growth during the historic period include the rising incidence of cancer, robust economic growth in developing markets, a boost in pharmaceutical R&D spending, elevated healthcare expenses, burgeoning governmental initiatives, a sturdy pipeline of medications, inexpensive biosimilars, and an uptick in patent expirations.

The size of the biosimilars market is forecasted to witness swift expansion in the upcoming years. It is projected to escalate to “$41.34 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 17.3%. Contributing factors to this growth during the predicted period include an increased incidence of cancer, the growing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), escalation in healthcare spending, the high potential of developing economies, advancements in technology, widespread use of biological drugs, an aging populace and enhanced healthcare accessibility. The primary trends predicted for the forecast period involve enhanced emphasis on intensive R&D initiatives for generating efficacious and innovative medications, emphasis on growth strategies through mergers and acquisitions, interest in creating strategic partnerships, increased investment, and an emphasis on the use of artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Forces Are Driving The Growth Of The Biosimilars Market?

An upswing in chronic conditions like arthritis, asthma, and cancer is envisioned to propel the biosimilars market. Factors such as lengthy work schedules, insufficient physical exertion, and poor diet and drinking patterns contribute to the pervasiveness of these chronic diseases. To counteract this, biosimilars are utilized more frequently as a remedy for these health problems. By stimulating the body’s immune response against cancer cells, biosimilars facilitate the removal of these damaging cells. A United Nations article states that by 2030, chronic diseases would account for 70% of worldwide mortality, and the global chronic disease rate is expected to rise to approximately 60%. Consequently, the escalating prevalence of chronic diseases boosts the demand for biosimilars, further energizing the biosimilars market.

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

How Are Key Trends Driving Expansion In The Biosimilars Industry?

In the biosimilars market, leading firms are concentrating on creating innovative products to establish a competitive advantage. AMJEVITA has been introduced as the inaugural U.S. biosimilar to Humira, a drug used by over a million patients dealing with specific severe inflammatory diseases. For example, in January 2023, Amgen Inc., a biotech company based in the U.S. launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now accessible in the U.S. The list price (wholesale acquisition cost) of AMJEVITA (40 mg) is 55% less than the existing Humira list price. Additionally, AMJEVITA is available at a list price that is 5% less than the present Humira price.

Which Companies Currently Dominate The Competitive Landscape In The Biosimilars Industry?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Geographic Regions Are Driving Demand In The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model